{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:25:22Z","timestamp":1791487522985,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-026-01120-7","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T10:02:35Z","timestamp":1773828155000},"page":"424-434","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Tucatinib\u2013trastuzumab\u2013capecitabine for treatment of leptomeningeal metastasis in women with HER2+ breast cancer: TBCRC049 phase 2 study results"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0103-4718","authenticated-orcid":false,"given":"Rashmi K.","family":"Murthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara J.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald A.","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6425-4400","authenticated-orcid":false,"given":"Akshara","family":"Singareeka-Raghavendra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Gule","family":"Monroe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7140-545X","authenticated-orcid":false,"given":"Jason","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Schwartz-Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Topletz-Erickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Lobbous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5895-6855","authenticated-orcid":false,"given":"Kristen","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Melisko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aki","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherise D.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1454-6461","authenticated-orcid":false,"given":"John F.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6380-5944","authenticated-orcid":false,"given":"Ian E.","family":"Krop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Valero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4284-5656","authenticated-orcid":false,"given":"Mothaffar F.","family":"Rimawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio C.","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5711-2404","authenticated-orcid":false,"given":"Debu","family":"Tripathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2263-5413","authenticated-orcid":false,"given":"Nancy U.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica M.","family":"Stringer-Reasor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"1120_CR1","doi-asserted-by":"publisher","first-page":"73312","DOI":"10.18632\/oncotarget.20272","volume":"8","author":"G Nayar","year":"2017","unstructured":"Nayar, G. et al. Leptomeningeal disease: current diagnostic and therapeutic strategies. Oncotarget 8, 73312\u201373328 (2017).","journal-title":"Oncotarget"},{"key":"1120_CR2","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1097\/WCO.0b013e3283322a92","volume":"22","author":"MC Chamberlain","year":"2009","unstructured":"Chamberlain, M. C. Leptomeningeal metastasis. Curr. Opin. Neurol. 22, 665\u2013674 (2009).","journal-title":"Curr. Opin. Neurol."},{"key":"1120_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1023\/A:1005976926058","volume":"37","author":"MC Chamberlain","year":"1998","unstructured":"Chamberlain, M. C. Leptomeningeal metastases: a review of evaluation and treatment. J. Neurooncol. 37, 271\u2013284 (1998).","journal-title":"J. Neurooncol."},{"key":"1120_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s11060-017-2452-6","volume":"133","author":"E Le Rhun","year":"2017","unstructured":"Le Rhun, E. et al. Diagnosis and treatment patterns for patients with leptomeningeal metastasis from solid tumors across Europe. J. Neurooncol. 133, 419\u2013427 (2017).","journal-title":"J. Neurooncol."},{"key":"1120_CR5","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s10549-014-3054-z","volume":"146","author":"S Abouharb","year":"2014","unstructured":"Abouharb, S. et al. Leptomeningeal disease and breast cancer: the importance of tumor subtype. Breast Cancer Res. Treat. 146, 477\u2013486 (2014).","journal-title":"Breast Cancer Res. Treat."},{"key":"1120_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.clbc.2016.07.002","volume":"17","author":"A Morikawa","year":"2017","unstructured":"Morikawa, A. et al. Characteristics and outcomes of patients with breast cancer with leptomeningeal metastasis. Clin. Breast Cancer 17, 23\u201328 (2017).","journal-title":"Clin. Breast Cancer"},{"key":"1120_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100150","volume":"6","author":"M Carausu","year":"2021","unstructured":"Carausu, M. et al. Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database. ESMO Open 6, 100150 (2021).","journal-title":"ESMO Open"},{"key":"1120_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/01.cad.0000236313.50833.ee","volume":"18","author":"HJ Stemmler","year":"2007","unstructured":"Stemmler, H. J. et al. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 18, 23\u201328 (2007).","journal-title":"Anticancer Drugs"},{"key":"1120_CR9","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/S1470-2045(18)30256-0","volume":"19","author":"R Murthy","year":"2018","unstructured":"Murthy, R. et al. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. Lancet Oncol. 19, 880\u2013888 (2018).","journal-title":"Lancet Oncol."},{"key":"1120_CR10","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1158\/1535-7163.MCT-19-0873","volume":"19","author":"A Kulukian","year":"2020","unstructured":"Kulukian, A. et al. Preclinical activity of HER2-selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models. Mol. Cancer Ther. 19, 976\u2013987 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"1120_CR11","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","volume":"382","author":"RK Murthy","year":"2020","unstructured":"Murthy, R. K. et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N. Engl. J. Med. 382, 597\u2013609 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1120_CR12","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1200\/JCO.20.00775","volume":"38","author":"NU Lin","year":"2020","unstructured":"Lin, N. U. et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J. Clin. Oncol. 38, 2610\u20132619 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR13","unstructured":"TUKYSA (Tucatinib) Tablets, for Oral Use. Prescribing information (Seagen, Inc., 2023); https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/213411s004lbl.pdf"},{"key":"1120_CR14","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/neuonc\/now197","volume":"19","author":"M Chamberlain","year":"2017","unstructured":"Chamberlain, M. et al. Leptomeningeal metastases: a RANO proposal for response criteria. Neuro Oncol. 19, 484\u2013492 (2017).","journal-title":"Neuro Oncol."},{"key":"1120_CR15","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1093\/neuonc\/nou089","volume":"16","author":"M Chamberlain","year":"2014","unstructured":"Chamberlain, M. et al. Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology criticalreview of endpoints and response criteria of published randomized clinical trials. Neuro Oncol. 16, 1176\u20131185 (2014).","journal-title":"Neuro Oncol."},{"key":"1120_CR16","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1016\/j.ejca.2004.08.012","volume":"40","author":"W Boogerd","year":"2004","unstructured":"Boogerd, W. et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur. J. Cancer 40, 2726\u20132733 (2004).","journal-title":"Eur. J. Cancer"},{"key":"1120_CR17","first-page":"3394","volume":"5","author":"MJ Glantz","year":"1999","unstructured":"Glantz, M. J. et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin. Cancer Res. 5, 3394\u20133402 (1999).","journal-title":"Clin. Cancer Res."},{"key":"1120_CR18","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1200\/JCO.1993.11.3.561","volume":"11","author":"SA Grossman","year":"1993","unstructured":"Grossman, S. A. et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J. Clin. Oncol. 11, 561\u2013569 (1993).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR19","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1200\/JCO.1987.5.10.1655","volume":"5","author":"RN Hitchins","year":"1987","unstructured":"Hitchins, R. N., Bell, D. R., Woods, R. L. & Levi, J. A. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J. Clin. Oncol. 5, 1655\u20131662 (1987).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR20","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/neuonc\/noz201","volume":"22","author":"E Le Rhun","year":"2020","unstructured":"Le Rhun, E. et al. Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer. Neuro Oncol. 22, 524\u2013538 (2020).","journal-title":"Neuro Oncol."},{"key":"1120_CR21","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1200\/jco.2006.24.18_suppl.1528","volume":"24","author":"WR Shapiro","year":"2006","unstructured":"Shapiro, W. R., Schmid, M., Glantz, M. & Miller, J. J. A randomized phase III\/IV study to determine benefit and safety of cytarabine liposome injection for treatment of neoplastic meningitis. J. Clin. Oncol. 24, 1528 (2006).","journal-title":"J. Clin. Oncol."},{"key":"1120_CR22","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/neuonc\/noac180","volume":"25","author":"F Oberkampf","year":"2023","unstructured":"Oberkampf, F. et al. Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis. Neuro Oncol. 25, 365\u2013374 (2023).","journal-title":"Neuro Oncol."},{"key":"1120_CR23","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/neuonc\/noac195","volume":"25","author":"PU Kumthekar","year":"2023","unstructured":"Kumthekar, P. U. et al. A phase I\/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: safety, efficacy, and cerebrospinal fluid pharmacokinetics. Neuro Oncol. 25, 557\u2013565 (2023).","journal-title":"Neuro Oncol."},{"key":"1120_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41523-023-00519-0","volume":"9","author":"L Alder","year":"2023","unstructured":"Alder, L. et al. Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan. npj Breast Cancer 9, 19 (2023).","journal-title":"npj Breast Cancer"},{"key":"1120_CR25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41523-023-00584-5","volume":"9","author":"N Niikura","year":"2023","unstructured":"Niikura, N. et al. Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and\/or leptomeningeal disease (ROSET-BM). npj Breast Cancer 9, 82 (2023).","journal-title":"npj Breast Cancer"},{"key":"1120_CR26","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/neuonc\/noaa152","volume":"23","author":"TJ Yang","year":"2021","unstructured":"Yang, T. J. et al. Clinical trial of proton craniospinal irradiation for leptomeningeal metastases. Neuro Oncol. 23, 134\u2013143 (2021).","journal-title":"Neuro Oncol."},{"key":"1120_CR27","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1158\/1078-0432.CCR-22-1138","volume":"29","author":"S Kabraji","year":"2023","unstructured":"Kabraji, S. et al. Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases. Clin. Cancer Res. 29, 174\u2013182 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1120_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000507","volume":"4","author":"E Le Rhun","year":"2019","unstructured":"Le Rhun, E., Preusser, M., van den Bent, M., Andratschke, N. & Weller, M. How we treat patients with leptomeningeal metastases. ESMO Open 4, e000507 (2019).","journal-title":"ESMO Open"},{"key":"1120_CR29","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1002\/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V","volume":"89","author":"CS Cleeland","year":"2000","unstructured":"Cleeland, C. S. et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 89, 1634\u20131646 (2000).","journal-title":"Cancer"},{"key":"1120_CR30","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/neuonc\/nox029","volume":"19","author":"L Nayak","year":"2017","unstructured":"Nayak, L. et al. The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro Oncol. 19, 625\u2013635 (2017).","journal-title":"Neuro Oncol"},{"key":"1120_CR31","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.4155\/bio-2022-0199","volume":"14","author":"JA Meyer","year":"2022","unstructured":"Meyer, J. A., DeChenne, S., Foerder, C. A. & Hengel, S. M. Bioanalysis of tucatinib and metabolite, and a five-way cross-validation to support clinical pharmacokinetic analysis. Bioanalysis 14, 1443\u20131452 (2022).","journal-title":"Bioanalysis"},{"key":"1120_CR32","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/0021-9681(61)90060-1","volume":"13","author":"EA Gehan","year":"1961","unstructured":"Gehan, E. A. The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J. Chronic Dis. 13, 346\u2013353 (1961).","journal-title":"J. Chronic Dis."},{"key":"1120_CR33","doi-asserted-by":"crossref","unstructured":"Brookmeyer, R. & Crowley, J. A confidence interval for the median survival time. Biometrics 38, 29\u201341 (1982).","DOI":"10.2307\/2530286"}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01120-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01120-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01120-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T08:55:25Z","timestamp":1774860925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01120-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["1120"],"URL":"https:\/\/doi.org\/10.1038\/s43018-026-01120-7","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"assertion":[{"value":"21 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.K.M. has received research funding (institutional) from Zanrong Pharma, Seattle Genetics, Pfizer, Daiichi Sankyo, Astra Zeneca and EMD-Serono and honorarium and\/or consulting fees from Sanofi, Novartis, Astra Zeneca, Pfizer, Genentech\/Roche, Seattle Genetics and Puma. B.J.O. has received research funding (institutional) from EMD-Serono, Seagen, consulting fees from Seagen and scientific and\/or advisory committee fees from PlusTherapeutics. D.A.B. is co-owner of Berry Consultants, LLC, a statistical consulting company. A.T.-E. has Seagen employment and\/or stocks. A.M. has received research funding (institutional) from Lilly, Merrimack, Novartis, Genentech and\/or Roche, Millenium Pharmaceuticals, Eisai, Seagen, Pfizer, Tempus, Molecular Templates, Dantari, Pharmaceuticals, Suzhou Zanrong Pharma, Merck Sharp & Dohme Corp and F. Hoffman LaRoche, consulting and\/or advisory fees from Eisai, Lilly, Seattle Genetics and other from Taiho Pharmaceutical. J.F.d.G. has received grant support from Carthera and HaiHe pharmaceuticals, consulting fees from MundiPharma, Insightec, Bioasis Technologies, Kintara, Kazia, Monteris, Karyopharm, Sumitomo Dainippon Pharma Oncology, Merck, Sapience Therapeutics, VBI Vaccines, Chimerix, Aucentra, Midatech, Telix Pharma, Alpha Pharmaceuticals and Servier and other from Alaunos and Brii Biosciences. M.F.R. has received research grants from Pfizer and Genentech and consulting honoraria from Macrogenics, Seagen, Novartis and AstraZeneca. N.U.L. has received contracts and\/or grant funding (institutional) from Genentech, Merck, Pfizer, Seattle Genetics, AstraZeneca, Zion Pharmaceuticals and Olema Pharmaceuticals, royalties from Up to Date and consulting fees from Puma, Seattle Genetics, Daiichi Sankyo, AstraZeneca, Prelude Therapeutics, Denali Therapeutics, Olema Pharmaceuticals, Aleta BioPharma, Affinia Therapeutics, Voyager Therapeutics, Janssen, BluePrint Therapeutics and Artera, Inc. and Stemline\/Menarini. E.M.S.-R. has received research support from S. G. Komen, Vfoundation, Breast Cancer Research Foundation of Alabama and NIH, clinical research (institutional) funding from Pfizer, Seagen, Tesaro, Lilly, Merck, Genetech, Calithera and Corcept Therapeutics, Inc., and consulting and\/or advisory fees from Lilly, Mylan, Novartis, Immunomedics, AstraZeneca, Seagen and Merck. A.C.W., A.S.-R., D.T., I.E.K., J.J., J.S.-G., J.W., K.R., M.G.M., M.L., M.M., S.D.F. and V.V. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}